This article is more than 5 years old. Information may no longer be current.

pSivida begins phase 2 trial of IOP-lowering eye drop treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PERTH, Australia — pSivida has begun a phase-2 clinical trial of its eye drop formulation of mifepristone, the company announced.

The study is evaluating the drug for managing increased IOP in patients receiving steroidal treatments for chronic eye diseases. The trial represents a novel use and delivery method for mifepristone, which the Food and Drug Administration has approved as a steroid blocker, according to a press release.